- Conditions
- Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
- Interventions
- Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 25 Years to 55 Years · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Congestive Heart Failure
- Interventions
- carvedilol controlled release, carvedilol immediate release
- Drug
- Lead sponsor
- CTI-1, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 75
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more
- Conditions
- Parkinson's Disease
- Interventions
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Aliso Viejo, California • Irvine, California + 17 more
- Conditions
- HIV Infections
- Interventions
- INCB009471, Placebo comparator
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
- Conditions
- Parkinson's Disease
- Interventions
- Accordion Pill™ Carbidopa/Levodopa, Sinemet®, Placebo -AP-CD/LD, Placebo- Sinemet
- Drug
- Lead sponsor
- Intec Pharma Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- CTC-501
- Drug
- Lead sponsor
- Chase Therapeutics Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Back Pain
- Interventions
- oxycodone IR, placebo, tapentadol IR
- Drug
- Lead sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 37
- States / cities
- Haleyville, Alabama • Tallassee, Alabama • Peoria, Arizona + 34 more
- Conditions
- Diabetes
- Interventions
- Saxagliptin, Metformin, Placebo, pioglitazone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 47
- States / cities
- Concord, California • Encinitas, California • Orange, California + 38 more
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary
- Interventions
- TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- COVID-19
- Interventions
- PF-06650833, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Dementia
- Interventions
- 1072nm infrared Photobiomodulation, Photobiomodulation SIMULATED
- Device
- Lead sponsor
- Quietmind Foundation
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Plymouth Meeting, Pennsylvania
- Conditions
- Pain
- Interventions
- TV-46763, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Anaheim, California • Bakersfield, California + 5 more
- Conditions
- NSCLC, Non Small Cell Lung Cancer
- Interventions
- OSI-906, Erlotinib, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- La Jolla, California • Tampa, Florida • Weston, Florida + 8 more
- Conditions
- Liver Cirrhosis
- Interventions
- Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet, Rifaximin SSD 80 mg SER tablet, Rifaximin SSD 80mgIR/80mgSER tablet
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more
- Conditions
- Parkinson Disease
- Interventions
- Isradipine, Placebo (for Isradipine)
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more
- Conditions
- Hyperlipidemia, Dyslipidemia
- Interventions
- NK-104-CR, Livalo® IR, Placebo (for NK-104-CR), Placebo (for Livalo® IR)
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 69
- States / cities
- Foley, Alabama • Huntsville, Alabama • Montgomery, Alabama + 66 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Salsalate, Placebo
- Drug · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- opana then darvocet then placebo, opana then placebo then darvocet, placebo then opana then darvocet, Placebo then darvocet then opana, Darvocet then opana then placebo, Darvocet then placebo then opana
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- Tolvaptan MR, Tolvaptan IR, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 31 more
- Conditions
- Abuse Potential
- Interventions
- Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Acute Pain
- Interventions
- Cebranopadol, Oxycodone IR, Placebo Only, Placebo
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Sheffield, Alabama • Little Rock, Arkansas • Tampa, Florida + 7 more
- Conditions
- Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
- Interventions
- Rifaximin SSD 40 mg IR tablet, Placebo
- Drug
- Lead sponsor
- Jasmohan Bajaj
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Overactive Bladder
- Interventions
- trospium chloride, oxybutynin IR, oxybutynin IR placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Acute Pain
- Interventions
- Oxymorphone immediate release
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more